Selected Quarterly Financial Data (Unaudited) |
Selected Quarterly Financial Data (Unaudited) The following are selected quarterly financial data for the years ended December 31, 2018 and 2017: | | | | | | | | | | | | | | | | | | Quarter Ended | | March 31, 2018 | | June 30, 2018 | | September 30, 2018 | | December 31, 2018 | Revenues | $ | 2,468 |
| | $ | 2,358 |
| | $ | 2,847 |
| | $ | 2,755 |
| Loss from operations | (9,908 | ) | | (7,860 | ) | | (6,417 | ) | | (5,148 | ) | Net loss | (10,747 | ) | | (8,664 | ) | | (7,223 | ) | | (5,941 | ) | Net loss per common share (basic and diluted) | $ | (0.33 | ) | | $ | (0.26 | ) | | $ | (0.22 | ) | | $ | (0.18 | ) | Weighted average common shares (basic and diluted) | 33,053,702 |
| | 33,135,391 |
| | 33,161,592 |
| | 33,121,666 |
|
| | | | | | | | | | | | | | | | | | Quarter Ended | | March 31, 2017 | | June 30, 2017 | | September 30, 2017 | | December 31, 2017 | Revenues | $ | 2,131 |
| | $ | 2,061 |
| | $ | 2,444 |
| | $ | 3,262 |
| Loss from operations | (15,053 | ) | | (13,109 | ) | | (14,471 | ) | | (7,127 | ) | Net loss | (15,742 | ) | | (14,090 | ) | | (15,457 | ) | | (8,028 | ) | Net loss per common share (basic and diluted) | $ | (0.55 | ) | | $ | (0.49 | ) | | $ | (0.53 | ) | | $ | (0.24 | ) | Weighted average common shares (basic and diluted) | 28,402,355 |
| | 28,757,341 |
| | 29,302,839 |
| | 32,801,650 |
|
The net loss amounts presented for the quarters ended March 31, 2017 and September 30, 2017 include milestone payments of $3.8 million made under the Company’s collaboration with Aurigene, which were recognized as research and development expenses (see Note 4(b)).
|